Boothbay Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Boothbay Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,400	Closed	-$7.23M	–	2120
2023 Q1	$7.23M	Buy	+71,400	New	+$7.43M	0.15%	144
2022 Q2	–	Sell	-30,800	Closed	-$2.89M	–	2528
2022 Q1	$2.89M	Buy	30,800 +13,900	+82%	+$1.18M	0.07%	418
2021 Q4	$1.44M	Buy	+16,900	New	+$1.55M	0.03%	604
2019 Q4	–	Sell	-192	Closed	-$1.73M	–	941
2019 Q3	$1.73M	Sell	192 -22	-10%	-$2.06K	0.16%	174
2019 Q2	$1.81M	Sell	214 -6	-3%	-$493	0.16%	162
2019 Q1	$1.94M	Buy	+220	New	+$18.4K	0.19%	129

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Boothbay Fund Management's NBIX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 11,814 shares worth $1.99M. The stake represents 0.03% of the portfolio and ranks #720 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in NBIX as recently as Q4 2025.

Boothbay Fund Management first reported a position in NBIX in Q4 2017 and has held it in 13 quarters since. The position peaked at $3.71M in Q1 2023. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Boothbay Fund Management held 11,814 shares of Neurocrine Biosciences worth $1.99M as of Q2 2026.
Neurocrine Biosciences was a new Boothbay Fund Management position in Q2 2026.
Neurocrine Biosciences made up 0.03% of Boothbay Fund Management's portfolio in Q2 2026, its #720 holding.
Boothbay Fund Management first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 13 quarters since.
Boothbay Fund Management's Neurocrine Biosciences position peaked at $3.71M in Q1 2023.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.